Download Free Medical BHIVA Guidelines for HIV-associated malignancies PowerPoint Presentation

BHIVA Guidelines for HIV-associated malignancies PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on anal cancer, which is titled "BHIVA Guidelines for HIV-associated malignancies", to know about the best clinical practice in HIV-associated malignancies, and, treatment and management of adults with HIV infection and malignancy.

Tags : anal cancer, Guidelines, HIV-associated malignancies, treatment, management, HIV infection, malignancy, AIDS-defining malignancies, Kaposi sarcoma, High grade B cell non-Hodgkin lymphoma, Invasive cervical cancer, Anal cancer, Hodgkin lymphoma, Multicentric Castleman’s disease, Testicular germ cell cancer, Non-small cell lung cancer, hepatocellular cancer

Published on : May 06, 2021 | Views : 1083 | Downloads : 0

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

BHIVA Guidelines for HIV-associated malignancies
Slide 2-

Scope and purpose Provide guidance on best clinical practice Treatment and management of adults with HIV infection and malignancy Do not address screening for malignancy in this population
Slide 3-

Methodology Modified GRADE system for review of evidence (Appendix 1) Multispecialty, multidisciplinary team – Oncology, Haematology, HIV, CNS, Pharmacy Patient involvement Two patient representatives involved in all aspects of guideline development Additional two meetings with patients and community representatives before writing group consensus meeting and as part of public consultation process
Slide 4-

SummaryHIV-associated Malignancies Increased risk of: AIDS-defining malignancies Kaposi sarcoma High grade B cell non-Hodgkin lymphoma Invasive cervical cancer Other malignancies Anal cancer Hodgkin lymphoma Multicentric Castleman’s disease Testicular germ cell cancer Non-small cell lung cancer Hepatocellular cancer Other cancers
Slide 5-

Summary For optimal care, need shared expertise and collaboration between Oncology, Haematology, HIV, Palliative Care physicians Clinical Nurse Specialists Pharmacists (see BHIVA Standards of Care for People Living with HIV 2013) Large centres of care with expertise and >5000 PLHIV Urgent referral of patients with suspected cancer, all to be seen within 2 weeks in specialist unit Test all for HIV Start cART for all patients diagnosed with cancer All require opportunistic infection (OI) prophylaxis
Slide 6-

3. Kaposi sarcoma (KS) Epidemiology KS is caused by KSHV/HHV-8 virus. Post-cART incidence of KS has decreased (0.3 vs 1.9/1000 person years, hazard ratio 7), survival has increased Management Always confirm histologically (1C) Test for HIV CT, bronchoscopy, endoscopy only required if symptomatic (2D) Start cART for all patients with KS (1B)
Slide 7-

3. Kaposi sarcoma (KS) Treatment T0 (early stage KS): cART ± local radiotherapy (RT) or intralesional vinblastine for cosmesis (2C) T1 (advanced stage KS): cART and chemotherapy (1B) First line: liposomal anthracyclines Either liposomal daunorubicin (DaunoXomeTM) 40 mg/m2 q14d or liposomal doxorubicin (CaelyxTM) 20 mg/m2 q21d (1A) Second line: if refractory to anthracycline Paclitaxel (TaxolTM) 100mg/m2 q14d (1C) Consider clinical trial
Slide 8-

4. Systemic AIDS-relatednon-Hodgkin lymphoma (NHL) Epidemiology HIV increases risk of NHL Second commonest tumour in PLWH High-grade B cell NHL is an AIDS-defining illness Presentation: advanced stage, B symptoms, extranodal disease including bone marrow is common cART reduces the risk of NHL Survival of NHL in PLWH is the now the same as that seen in HIV-negative people Prognosis depends on histological subtype and stage
Slide 9-

4. Systemic AIDS-relatednon-Hodgkin lymphoma (NHL) Management Confirm histologically, requires expert review HIV test Clinical evaluation, bloods (Table 4.1), CT, bone marrow aspirate and trephine, FDG-PET at diagnosis improves staging accuracy, CSF if CNS symptoms or involvement of paranasal sinuses, breast, paraspinal disease, testes, renal, epidural space, bone
Slide 10-

4. NHL: systemic AIDS-related diffuse large B-cell lymphoma (DLBL) Treatment Start cART, opportunistic infection prophylaxis and chemotherapy (1B) First-line chemotherapy as for HIV-negative patients CHOP or EPOCH Add rituximab (1B) for CD20+ NHL If CD4 <50 cells/ml, close monitoring advised, OI prophylaxis, G-CSF and prompt OI treatment If high risk of CNS relapse (high LDH, extranodal disease and high-risk sites involved) CNS prophylaxis (intrathecal (IT) and/or IV methotrexate) as for HIV-negative patients (1C)
Slide 11-

4. NHL: Burkitt lymphoma (BL) High risk of CNS disease Treatment Start cART, opportunistic infection prophylaxis and chemotherapy (1B) First-line chemotherapy CODOX-M/IVAC or DA-EPOCH (1B) Add rituximab (1C) Offer all BL patients prophylactic IT chemotherapy (1B)
Slide 12-

4. NHL: relapsed/recurrent systemic NHL Relapsed/aggressive NHL Second-line chemotherapy (1C) may contain platinum (2C) If response (CR or PR), consider high-dose therapy (HDT) with autologous stem cell transplantation (ASCT)
Slide 13-

5. NHL: primary CNS lymphoma (PCNSL) Epidemiology Poor prognosis cART reduces risk Diagnosis Presentation may be subacute/neuropsychiatric Craniospinal involvement only, no systemic involvement HIV test Clinical assessment, bloods including LDH, CT/MRI brain, CSF (if safe) include EBV PCR on CSF, CT CAP, USS testes Confirm histologically: brain biopsy is the only confirmatory test Treatment Start cART (1C) All patients with adequate performance status: consider treatment with regimen containing high-dose methotrexate (1D) Use whole-brain radiotherapy (RT) for palliation for symptom control or, as alternative to first-line treatment if risk of toxicity from high-dose IV agents unacceptable (1C)
Slide 14-

6. NHL: primary effusion lymphoma (PEL) Epidemiology 3% of HIV-associated NHL Poor prognosis Lymphomas immunostain for HHV8 (+/-EBV) Diagnosis Requires expert histopathology review Usually causes pleural or pericardial effusion or ascites without masses Rare extracavity PEL presents with solid masses rather than effusions Diagnosis from effusion: cellular morphology, immune phenotype, virology HIV test Treatment Chemotherapy plus cART and opportunistic infection prophylaxis (1C) CHOP-like regimens (2C) Consider clinical trial
Slide 15-

7. NHL: plasmablastic lymphoma Epidemiology 2.6% of HIV-associated lymphomas Three types: oral mucosal (EBV+ve); extra-oral (GIT, skin, nodal, splenic) (EBV+ve); associated with multicentric Castleman’s disease (HHV8+ve) Requires expert histopathology review HIV test Treatment Chemotherapy plus cART and opportunistic infection prophylaxis (1C) Chemotherapy: anthracycline-containing regimen (1C)
Slide 16-

8. Cervical intraepithelial neoplasia (CIN) and cervical cancer Epidemiology Related to high-risk HPV (mostly 16 and 18) Cervical cancer preceded by CIN 75% cases cervical cancer preventable by screening Smoking increases risk No change in risk of cervical cancer post cART Driven by HPV Increased risk of cervical cancer due to HIV much smaller than increase in HIV-related KS/NHL Survival bias masks effect as PLWH population lives longer Modest decreased incidence of CIN post cART Increased incidence of CIN with low CD4 cell counts Screening All HIV-infected women have annual cytology (and initial colposcopy if resources permit) (2C) Same age range as for HIV-negative women (1B)
Slide 17-

8. Cervical intraepithelial neoplasia (CIN) and cervical cancer Management HIV test CIN 1 Less severe grades than CIN2: no treatment as it represents persistent HPV infection not pre-malignancy (2B) CIN 2/3 Manage as per UK guidelines Excision: higher failure rate than in HIV-negative patients as high frequency of compromised margins on excisional specimens; higher rates of treatment failure Start cART: relapse less frequent with CD4 count >200cells/ml and undetectable HIV viral load Invasive cervical cancer Manage as per UK guidelines for HIV-negative women within MDT framework (1B)
Slide 18-

9. Anal cancer Epidemiology Relative risk 40–50 in HIV-positive MSM Occurs at younger age in PLWH Associated with high-risk HPV (mostly 16 and 18) Incidence rising in post-cART era May be due to longer survival with HIV allowing time for progression from HPV to AIN to invasive anal cancer Diagnosis Role of annual cytology and anoscopy not proven: patients encouraged to check and report lumps in anal canal (BHIVA BASHH FFPRHC 2008 guidelines on anal cancer in HIV) Patients may present with rectal bleeding, anal pain, incontinence, but may be asymptomatic EUA anal canal and rectum, and biopsy all suspected cases (1D) Further staging CT CAP, MRI pelvis (1B)
Slide 19-

9. Anal cancer Management HIV test Manage in specialist centres with experience (1C) Centres managing anal cancer should be able to provide high resolution anoscopy (HRA) (2D) Treatment Start cART (1C) Start OI prophylaxis (1D) Chemoradiotherapy (CRT) with 5-flourouracil and mitomycin C (1A) Salvage surgery may be appropriate if loco-regional disease resistance or relapse following CRT (2D) Best supportive care may be more appropriate if metastatic disease or local relapse following salvage surgery (2D) Advocate surveillance for AIN by HRA (2D)
Slide 20-

10. Hodgkin lymphoma Epidemiology Commoner in PLWH x10–20 Post-cART rates for CR/overall survival/disease-free survival same asfor HIV-negative patients Increased incidence with CD4 <200 cells/ml, and CD4 count mayfall 1 year pre-HL diagnosis EBV-driven Diagnosis Presentation in HIV infection: advanced stage, more symptoms, extranodal disease, poor performance status Histology EBV+ and mostly mixed cellularity (MC) or lymphocyte-depleted (LD), rather than nodular sclerosis Management HIV test Start cART and opportunistic infection prophylaxis (1A) Avoid ritonavir: risk of vinblastine-mediated neuropathy and neutropenia (1D)
Slide 21-

10. Hodgkin lymphoma Management First-line ABVD-based regimens Early favourable: ABVD x2–4 + IFRT 20–30Gy (1B) Early unfavourable: ABVD x4 + IFRT 30Gy (1B) Advanced ABVD: x6–8 +/- RT (1B) Relapse/refractory HL Salvage chemotherapy If chemosensitive, consolidate with HDT/ASCR (1B) Assess response to treatment: FDG-PET scan and bone marrow biopsy (1D) Assess during FU 2–4 monthly for 2 years then 3–6 monthly for a further 3 years (1B) If blood products required: give irradiated blood products
Slide 22-

11. Multicentric Castleman’s disease (MCD) Epidemiology HHV8-driven: present in all instances; rise in plasma HHV8 at relapse cART does not prevent MCD: can present CD4 >200 cells/ml Risk of NHL x15 higher than in PLWH without MCD Diagnosis Relapsing and remitting course Biopsy lymph node histology: confirmatory stain for HHV8 and IgM lambda (2B) Requires expert histopathology review High HHV-8 blood level supports diagnosis (2C) HIV test Treatment First line: rituximab (1B) Start cART and opportunistic infection prophylaxis Aggressive disease add chemotherapy (1C) Relapse: re-treat with rituximab (1C) Monitor Measure HHV-8 level in blood (1C) Rise can predict relapse (2D)
Slide 23-

12. Testicular germ cell cancer Epidemiology Seminoma more frequent in HIV infection 3.7% RR Younger age Risk of over-staging due to HIV-associated lymphadenopathy Management HIV test Chemotherapy plus cART and opportunistic infection prophylaxis (2C) Treatment the same as for HIV-negative population (2C) Surveillance is safe for stage I disease (2C) Bleomycin can be avoided in stage I disease as low-risk (2D)
Slide 24-

12. Non-small cell lung cancer Epidemiology Increased risk in PLWH Smoking, younger Management Biopsy, CT CAP including adrenals, bone scan, (interpret FDG-PET with caution – low specificity), cranial imaging if symptoms HIV test Stop smoking (1B) Offer potentially curative surgery when appropriate (2C) Screen for activating endothelial growth factor (EGFR) mutations. If present treat with tyrosine kinase inhibitors (TKIs) (2D) No role for screening for lung cancer in PLWH
Slide 25-

12. Hepatocellular carcinoma (HCC) Epidemiology Western world: 30% PLWH co-infected with hepatitis C (HCV) (75% IVDU) High hepatitis B (HBV) viral load: increased risk HCC Low CD4 cell count: increased risk hepatitis B-associated HCC Management HIV test CT CAP to exclude metastases, liver USS, AFP, assess cirrhosis (fibroscan, liver biopsy) Treat HCC same as in HIV-negative people (2C) Consider liver transplantation as appropriate as for HIV-negative people (2D) Sorafenib is an option for advanced, inoperable HCC (2D) Screen cirrhotic HBV and HCV co-infected patients with liver USS (1A) and 6 monthly AFP (2C) Consider screening non-cirrhotic HBV co-infected patients for HCC
Slide 26-

12. Other cancers Colorectal cancer Increased risk of adenoma and adenocarcinoma in PLWH Younger, more advanced disease, right-sided cancers Chemotherapy and cART and opportunistic infection prophylaxis Skin cancer Increased risk x5 SCC, BCC and x2–3 melanoma Atypical presentation HPV-driven cancers cART and opportunistic infection prophylaxis and treatment Merkel cell carcinoma (MCC)
Slide 27-

12. Other cancers Cutaneous lymphoma Mycosis fungoides, Sézary syndrome Penis precancer (PIN) and cancer PIN: increased risk in uncircumcised men Penile cancer x5–6 increased risk Other cancers AML more aggressive, increased deaths OIs Head, neck and breast cancer – more aggressive Prostate cancer Management HIV test, cART and opportunistic infection prophylaxis Standard care, large centre with MDT expertise
Slide 28-

13. Opportunistic infection (OI) prophylaxis All PLWH requiring cancer treatment should be on cART (1B) Pneumocystis jirovecii pneumonia (PCP) CD4 <200 cells/ml (1A), consider at higher levels when giving chemo/RT (also protects against cerebral Toxoplasma gondii). Co-trimoxazole Mycobacterium avium complex (MAC) CD4 <50 cells/ml (1B) or if risk of CD4 falling below this level. Azithromycin Fungal infections Systemic azole for all chemo/RT (1D) Bacterial infections Co-trimoxazole for PCP prophylaxis may provide some protection against bacterial infections (1C) Routine fluoroquinolone prophylaxis not recommended in low-risk patients
Slide 29-

13. Opportunistic infection (OI) prophylaxis Herpes simplex virus (HSV) Prophylaxis (aciclovir) recommended during chemotherapy (1D) Influenza virus Annual vaccination (1B) Pneumococcus Vaccination (1D) Hepatitis B virus (HBV) Vaccination (1D) Hepatitis B virus core antibody positive Treat with prophylactic antivirals in line with BHIVA hepatitis guidelines (1B). (If on cART, Truvada-containing regimen will provide this)